Clenbuterol
Active material: Clenbuterol
When ATH: R03CC13
CCF: Bronchodilators – beta2-adrenomimetik
When CSF: 12.01.01.02.01
Manufacturer: BALKANPHARMA-TROYAN AD (Bulgaria)
DOSAGE FORM, COMPOSITION AND PACKAGING
Syrup in the form of a transparent, colourless liquid with a characteristic smell of raspberries.
| 1 ml | |
| Clenbuterol hydrochloride | 1 g |
Excipients: sorbitol, glycerol, propylene glycol, sodium citrate dihydrate, lemon acid, metilparagidroksiʙenzoat, propilparagidroksibenzoat, butilparagidroksibenzoat, Sodium benzoate, Raspberry essence, Purified water.
100 ml – vials of dark glass (1) complete with measuring spoon – packs cardboard.
DESCRIPTION OF ACTIVE SUBSTANCES
Pharmacological action
Bronholitik, β is a stimulant2-adrenoretseptorov prolonged action. Bronchodilatory effect due to the direct relaxing effect on the muscles of the bronchi. Can increase HEART RATE. He has also tokolitičeskim effect.
Pharmacokinetics
Provides a high degree of absorption. High concentrations up in the plasma through 15 minutes after a single reception and persist for 7-24 no. Report mostly kidneys. T1/2 – 3 no.
Testimony
Prevention and relief of bronchospasm in bronchial asthma; bronchitis with BOS syndrome.
Dosage regimen
Taken orally at a dose of 2.5-20 mg 2 times / day. Dose set depending on patient age and clinical situation.
Side effect
Cardio-vascular system: tachycardia, arrythmia, low blood pressure.
CNS: jitter fingers, anxiety, headache.
From the digestive system: dry mouth, nausea.
Allergic reactions: the appearance of skin rash.
Other: kaliopenia.
Contraindications
Thyrotoxicosis, tachycardia, integuments, subaortalny stenoses rivers, acute phase of myocardial infarction, pregnancy, hypersensitivity to klenbuterolu.
Pregnancy and lactation
Contraindicated during pregnancy.
Cautions
Possible development of resistance and syndrome “Ricochet”.
We cannot allow the drug in the eye, especially in glaucoma.
Drug Interactions
Beta-adrenoblokatora are pharmacological antagonists of Clenbuterol and can resolve it.
Clenbuterol reduces effect gipoglikemicakih funds. Increases the risk of development of intracardiac conduction together with MAO inhibitors and theophylline. Increases toxicity of cardiac glycosides and increases the risk of arrhythmia. In combination with simpatomimeticakimi means going mutual increase toxicity.
